Alpha Emitter Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Alpha Emitter Market Size Analysis

Global Alpha Emitter Market Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value

North America Market Analysis

Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value
U.S.
1. By Type of Radionuclide
  1. Introduction
    1. Type of Radionuclide By Value
  2. Astatine-211
    1. By Value
  3. Radium-223
    1. By Value
  4. Actinium-225
    1. By Value
  5. Lead-212
    1. By Value
  6. Bismuth-212
    1. By Value
  7. Other Radionuclides
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Prostate Cancer
    1. By Value
  3. Bone Metastasis
    1. By Value
  4. Ovarian Cancer
    1. By Value
  5. Pancreatic Cancer
    1. By Value
  6. Endocrine Tumors
    1. By Value
  7. Other Applications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Centers
    1. By Value
  4. Other End Users
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value
U.K.
1. By Type of Radionuclide
  1. Introduction
    1. Type of Radionuclide By Value
  2. Astatine-211
    1. By Value
  3. Radium-223
    1. By Value
  4. Actinium-225
    1. By Value
  5. Lead-212
    1. By Value
  6. Bismuth-212
    1. By Value
  7. Other Radionuclides
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Prostate Cancer
    1. By Value
  3. Bone Metastasis
    1. By Value
  4. Ovarian Cancer
    1. By Value
  5. Pancreatic Cancer
    1. By Value
  6. Endocrine Tumors
    1. By Value
  7. Other Applications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Centers
    1. By Value
  4. Other End Users
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value
China
1. By Type of Radionuclide
  1. Introduction
    1. Type of Radionuclide By Value
  2. Astatine-211
    1. By Value
  3. Radium-223
    1. By Value
  4. Actinium-225
    1. By Value
  5. Lead-212
    1. By Value
  6. Bismuth-212
    1. By Value
  7. Other Radionuclides
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Prostate Cancer
    1. By Value
  3. Bone Metastasis
    1. By Value
  4. Ovarian Cancer
    1. By Value
  5. Pancreatic Cancer
    1. By Value
  6. Endocrine Tumors
    1. By Value
  7. Other Applications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Centers
    1. By Value
  4. Other End Users
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value
UAE
1. By Type of Radionuclide
  1. Introduction
    1. Type of Radionuclide By Value
  2. Astatine-211
    1. By Value
  3. Radium-223
    1. By Value
  4. Actinium-225
    1. By Value
  5. Lead-212
    1. By Value
  6. Bismuth-212
    1. By Value
  7. Other Radionuclides
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Prostate Cancer
    1. By Value
  3. Bone Metastasis
    1. By Value
  4. Ovarian Cancer
    1. By Value
  5. Pancreatic Cancer
    1. By Value
  6. Endocrine Tumors
    1. By Value
  7. Other Applications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Centers
    1. By Value
  4. Other End Users
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type of Radionuclide
1. Introduction
  1. Type of Radionuclide By Value
2. Astatine-211
  1. By Value
3. Radium-223
  1. By Value
4. Actinium-225
  1. By Value
5. Lead-212
  1. By Value
6. Bismuth-212
  1. By Value
7. Other Radionuclides
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Prostate Cancer
  1. By Value
3. Bone Metastasis
  1. By Value
4. Ovarian Cancer
  1. By Value
5. Pancreatic Cancer
  1. By Value
6. Endocrine Tumors
  1. By Value
7. Other Applications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic Centers
  1. By Value
4. Other End Users
  1. By Value
Brazil
1. By Type of Radionuclide
  1. Introduction
    1. Type of Radionuclide By Value
  2. Astatine-211
    1. By Value
  3. Radium-223
    1. By Value
  4. Actinium-225
    1. By Value
  5. Lead-212
    1. By Value
  6. Bismuth-212
    1. By Value
  7. Other Radionuclides
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Prostate Cancer
    1. By Value
  3. Bone Metastasis
    1. By Value
  4. Ovarian Cancer
    1. By Value
  5. Pancreatic Cancer
    1. By Value
  6. Endocrine Tumors
    1. By Value
  7. Other Applications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Centers
    1. By Value
  4. Other End Users
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Alpha Emitter Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Bayer AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Novartis AG
Actinium Pharmaceuticals Inc.
Alpha Fusion
Fusion Pharmaceuticals Inc.
Telix Pharmaceuticals Ltd
Alpha Tau Medical Ltd
IBA Radiopharma Solutions
RadioMedix Inc.
Orano Med SAS
Curium Pharma
BWXT Medical Ltd
Cardinal Health Inc.
Eckert & Ziegler
ITM Isotopen Technologien Mnchen SE
Nucleus RadioPharma
ARTBIO
Cyclotek Australia Pty Ltd
SHINE Technologies LLC

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment